Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | -52.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.14 | N/A | -52.17% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions. They did not provide a clear outlook for future performance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges faced during the quarter.
Veracyte's earnings report indicates a challenging quarter, with a significant miss on EPS. The stock reacted negatively, declining by 0.88%, reflecting investor concerns about the lack of guidance and transparency regarding future performance. This uncertainty may impact investor confidence going forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GRUPO AEROMEXICO S A ADR
Feb 16, 2021